«T cell recognition of human cancer – cracking the code»

30.10.2025 12:30 – 13:30

Clinically active cancer immunotherapies, including immune checkpoint blockade and TIL therapy, exert their activity by boosting T cell recognition of cancer cells. Furthermore, work by us and others has demonstrated that a substantial part of this tumor-specific T cell response is directed against cancer neoantigens that are unique to each individual tumor. While it is readily feasible to describe which TCR sequences are enriched at tumor sites, we presently lack the capacity to predict the antigen specificity of these TCRs. Development of such predictive algorithms would open up major new possibilities for both patient response prediction and the design of novel cancer immunotherapies. In addition, such capacities could find diagnostic utility in a range of other human conditions.

With the long-term mission to ‘crack the cancer recognition code’ we have created technologies to measure functional TCR signaling in high-throughput semi-synthetic systems. Recent and ongoing work towards a detailed understanding of TCR specificity will be described.

Hôtes: Pr Mikaël PITTET & Pr Olivier MICHIELIN
Centre de recherche translationnelle en onco-hématologie (CRTOH)
Département de médecine, Faculté de médecine UNIGE & Département d’oncologie, HUG

Lieu

Bâtiment: CMU

Auditoire Müller

entrée libre

Fichiers joints

afficheA3_FIB_Schumacher.pdf

137.5 Kb